Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01373203
Other study ID # 99077
Secondary ID
Status Active, not recruiting
Phase N/A
First received June 13, 2011
Last updated June 13, 2011
Start date January 2011
Est. completion date December 2011

Study information

Verified date June 2011
Source Taipei Medical University WanFang Hospital
Contact n/a
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Observational

Clinical Trial Summary

The important character of acute lung injury (ALI) is alveolar capillary membrane damage caused by different diseases, such as sepsis, trauma and shock. One of the important pathological stages is the varying degrees of interstitial fibrosis and semi-permeable alveolar membrane fibrosis. It has been proved that CXCL12/SDF-1 (stromal cell-derived factor-1) induces fibrocyte migration, and promotes fibrosis progression. Study indicated that inhibition of TLR4 receptor signaling pathway improves fibrosis progression induced by ALI, however, the role of fibrocyte in ALI is still unclear. The fibrocytes was significantly increased in asthmatic patients with pulmonary fibrosis, which companies with increased CTGF expression. Therefore, this project assumes that fibrocyte will differentiation to fibroblast/myofibroblast in patient with acute lung injury, which in turn leads to progression of fibrosis. The central hypothesis of this project is that peripheral progenitor cell fibrocytes play an important role in alveolitis caused by acute lung injury. The overall objective of this project is to study the role of fibrocytes in acute lung injury.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date December 2011
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Acute Lung Injury patients

- Above 20 years old

- Bilateral lung infiltrates

- PaO2/FiO2<300mmHg

- PCWP<18mmHg

Exclusion Criteria:

- Pregnant women

- Under 20 years old

- Hb<8.0mg/dl

Study Design

Observational Model: Case-Only


Related Conditions & MeSH terms


Locations

Country Name City State
Taiwan Taipei Medical University - WanFang Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
Taipei Medical University WanFang Hospital

Country where clinical trial is conducted

Taiwan,